Toward the development of α1a adrenergic receptor antagonists

被引：36

作者：

Bock, MG ^{[1
]}

Patane, MA ^{[1
]}

机构：

[1] Merck Res Labs, West Point, PA 19486 USA

来源：

ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 35 | 2000年 / 35卷

关键词：

D O I：

10.1016/S0065-7743(00)35021-7

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

引用

页码：221 / 230

页数：10

共 84 条

[1]

Adkison K K, 1998, Pharm Biotechnol, V11, P423

[2]

Akiyama K., 1997, Neurourology and Urodynamics, V16, P492

[3]

Akiyama K, 1999, J PHARMACOL EXP THER, V291, P81

[4] The concept of uroselectivity [J].

Andersson, KE .

EUROPEAN UROLOGY, 1998, 33 :7-11

[5]

Blue D. R. Jr., 1996, Neurourology and Urodynamics, V15, P345

[6]

Blue David R. Jr., 1997, Journal of Urology, V157, P190

[7]

Blue DR, 1997, BRIT J PHARMACOL, V120, pP107

[8] (+)-NIGULDIPINE BINDS WITH VERY HIGH-AFFINITY TO CA-2+ CHANNELS AND TO A SUBTYPE OF ALPHA-1-ADRENOCEPTORS [J].

BOER, R ;

GRASSEGGER, A ;

SCHUDT, C ;

GLOSSMANN, H .

EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, 1989, 172 (02) :131-145

[9] ALPHA-ADRENERGIC BLOCKERS IN PROSTATISM [J].

BOREHAM, PF ;

BRAITHWAITE, P ;

MILEWSKI, P ;

PEARSON, H .

BRITISH JOURNAL OF SURGERY, 1977, 64 (10) :756-757

[10]

Brawer M K, 1993, Arch Fam Med, V2, P929, DOI 10.1001/archfami.2.9.929

← 1 2 3 4 5 6 7 8 9 →